AlphaMab Oncology

Executive Summary

AlphaMab Oncology is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to developing innovative oncology therapeutics with a focus on bispecific antibodies and antibody-drug conjugates (ADCs). Leveraging proprietary platforms such as glycan-specific conjugation for ADCs, Fc-based CRIB technology for bispecifics, and subcutaneous formulation technologies, the company targets HER2-positive breast cancer and other solid tumors. Founded in 2020 and now public, AlphaMab has rapidly advanced its pipeline to Phase 3 trials, indicating strong execution and promising preclinical and clinical data. The company's differentiated approach aims to improve upon existing HER2-targeted therapies by enhancing efficacy, reducing toxicity, and enabling subcutaneous administration, which could offer significant competitive advantages in the large oncology market.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 Data Readout for Lead Bispecific Antibody in HER2-Positive Breast Cancer65% success
• Q3 2026Regulatory Submission for ADC Candidate in Solid Tumors50% success
• Q4 2026Strategic Partnership or Licensing Deal for Subcutaneous Formulation Platform40% success